French biotech CellProthera welcomes three exceptional talents to its executive management team
17.11.2021 18:43:00 EET | Business Wire | Press release
CellProthera SAS, a clinical stage biotechnology company developing a novel cell therapy for the regeneration of damaged heart tissue and other impaired organs, has strengthened its executive management team to foster the development of its main clinical program and extend it to new therapeutic indications.
Ibon Garitaonandia is appointed Chief Scientific Officer (CSO). His extensive experience in drug discovery and in the development of novel stem cell products will accelerate the translation of CellProthera’s cell therapy platform into new treatments for regenerative medicine. He has 15 years’ experience in stem cell research and regenerative medicine, and has worked at the Richmond Research Institute in London, Histocell in Spain and International StemCell Corporation in California, the first company to receive global regulatory approval to conduct a human pluripotent stem cell-based clinical trial for Parkinson’s disease.
Henk Streefkerk, MD PhD, takes the role of Chief Medical Officer (CMO). He brings decades of leadership in clinical research to boost the strategic development of the company and advance its pipeline of novel therapeutic solutions. After graduating from the University Medical Center Utrecht, Henk worked as Clinical Pharmacologist for Organon/Schering-Plough in the Netherlands. He then joined Actelion in Switzerland before taking the positions of Translational Medicine Expert and later Senior Brand Safety Leader with Novartis in Basel. After Novartis, he worked as Medical Director and Chief Medical Officer of a biotech specialized in oncology in Basel.
Olivier Friedrich is appointed Chief Financial Officer (CFO). His solid history of helping companies and start-ups to scale up in their development journey is key for CellProthera as it enters its next stage of development. A lecturer at EM Strasbourg in Finance and Regulation, Olivier brings 15 years of experience in corporate finance, internal control, accounting and tax matters. He held leadership positions with Ernst & Young for more than 10 years, leading financial audits and due diligence transactions for a wide spectrum of industrial firms and as CFO, supporting the cash and financing management of listed companies in the energy and car industry.
“The arrival of these three talents - all experts in their field - in the executive management team is a great boost to our ambitious, multi-indications development program and position us ideally to accelerate our pathway to market.", stated Matthieu de Kalbermatten, Chairman of CellProthera. “The wealth of their international experience will be useful to shape and steer the company effectively during the next clinical and regulatory stages.”
CellProthera develops a medical innovation that enables a heart damaged by a heart attack to regenerate by injecting stem cells originated from the patient's own blood.
As such, each patient becomes his own source of medicine!
The stem cell product ProtheraCytes® is obtained from a proprietary technology developed by CellProthera. It is injected into the heart tissue to be regenerated. In a few months, the heart muscle will regain its functionality, thus avoiding future treatments that are often severe, and in some cases, the need for a heart transplant.
Contact us! www.cellprothera.com/fr/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006054/en/
Contact information
Press contact: Mediatiser – Antoine Monnier / amonnier@mediatiser.tv
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New AI Research from GFT Technologies: 84% of CIOs Have Canceled an AI Project Over Legacy System Limits29.9.2026 15:07:00 EEST | Press release
A new AI study from GFT Technologies, an AI-centric global digital transformation company, finds that legacy infrastructure is one of the biggest obstacles to enterprise AI success, with the vast majority of technology leaders reporting it has forced them to abandon AI initiatives. The GFT survey, conducted by Wakefield Research among 945 CIOs and CTOs across 19 countries at companies with at least $500M in annual revenue (fielded August 11-31, 2026), reveals that AI's promise and its risks are accelerating in tandem. Key themes include legacy infrastructure undermining AI initiatives, skepticism over AI's return on investment, geopolitical and regulatory uncertainty reshaping strategy, distrust of how companies explain workforce decisions, and rising personal risk for technology leaders. “AI adoption is moving quickly, but our research shows that enterprises are increasingly recognizing the importance of the foundation underneath it. For many organizations, legacy infrastructure is be
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO ® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America29.9.2026 15:00:00 EEST | Press release
Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. Under the terms of the agreement, Knight will be responsible for seeking the necessary regulatory approvals and commercialising mogamulizumab for mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of CTCL, a rare non-Hodgkin’s lymphoma, in Argentina, Brazil, Colombia and Mexico. Knight will hold exclusive distribution rights for the medicine in these markets. Kyowa Kirin and Knight’s collaboration aims to support CTCL patients and improve their access to innovative therapies in Latin America. Céline Rhême, Cluster General Manager, Emerging Growth Markets, Kyowa Kirin, commented: “CTCL is more common in this region than many realise, and further work is needed to identify unmet needs and
Heaviside Industries Awarded $99M IDIQ Contract to Provide MOTH Spectrum Analyzers to U.S. Army29.9.2026 15:00:00 EEST | Press release
Heaviside Industries, a builder of multi-domain precision munitions platforms, announced it has been awarded a $99 million firm-fixed-price, indefinite delivery, indefinite quantity (IDIQ) contract by the U.S. Army to deliver its MOTH radio frequency (RF) spectrum analyzers in support of the Army’s electromagnetic spectrum operations (EMSO) priorities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929455358/en/ The five-year contract was awarded by U.S. Army Contracting Command at Aberdeen Proving Ground, Maryland and includes system procurement, fielding, upgrades, and sustainment. As unmanned systems proliferate and adversaries increasingly exploit the electromagnetic spectrum, the Army requires EMSO capabilities that are scalable, adaptable, and rapidly fieldable to maintain an advantage in the spectrum. Heaviside’s MOTH meets this need with real-time, passive RF detection in a low size, weight, power, and cost system
Royal Yacht International Represents Buyer in Landmark 132M Lürssen as Founder Predicts: “The Billion-dollar Yacht Is Coming”29.9.2026 15:00:00 EEST | Press release
Royal Yacht International has announced PROJECT M, a fully custom 132-metre Lürssensuperyacht exceeding 6,000 GT. But for Royal Yacht International Founder and CEO Tommaso Chiabra, the project is less about size than what it represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928365204/en/ Project M At the very top of the luxury market, the world’s most exceptional yachts are becoming increasingly difficult to reproduce. Only a small number of shipyards can execute projects of this scale. Construction takes years. Specialist capacity is finite. Build slots are scarce. And replacement cost can change dramatically between contract signing and delivery. “People look at purchase price. Sophisticated owners look at replacement value. What would somebody have to spend, and how long would they have to wait, to recreate your yacht when it is delivered?” For RYI, this is changing the role of the yacht broker. HUNDREDS OF MI
Create Apps Championship Winners Highlight Dubai’s Strength as a Base for Scaling Digital Businesses29.9.2026 14:49:00 EEST | Press release
Winners of past editions of Dubai Chamber of Digital Economy’s Create Apps Championship have highlighted how Dubai is helping entrepreneurs transform promising ideas into scalable digital ventures, with the championship playing a key role in supporting their growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929068961/en/ During Create Apps Championship 2025 (Photo: AETOSWire) Launched in 2023 as part of the ‘Create Apps in Dubai’ initiative, the championship supports participants through specialised training, mentorship, connections with investors and partners, and funding to develop and launch winning apps. Mariam Mohammed Almarri, Co-Founder of Boom, said: “A major milestone in our journey was participating in the Create Apps Championship, where Boom was recognised as ‘Dubai’s App of the Year 2025’ and ‘Most Impactful App’. This recognition enabled us to build Boom and transport it from an idea into a real product.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom